Surmodics, Inc Expects FY23 Revenue $130M-$132M (Prior $103M-$106M) Vs $116.95M Est, Adj EPS Loss $(0.29)-$(0.14) (Prior $(1.98)-$(1.68)) Vs $(1.3) Est
Portfolio Pulse from Benzinga Newsdesk
Surmodics, Inc has revised its FY23 revenue guidance to $130M-$132M, up from the previous $103M-$106M. The company also expects a smaller GAAP diluted loss per share of $(0.55) to $(0.40), and a Non-GAAP diluted loss per share of $(0.29) to $(0.14).
August 04, 2023 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Surmodics has increased its FY23 revenue guidance and expects a smaller loss per share, which could positively impact its stock.
Surmodics has revised its FY23 revenue guidance upwards and expects a smaller loss per share. This indicates improved financial performance, which is likely to be viewed positively by investors and could lead to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100